Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Dawson James gives an ultra conservative price target of $21. It excludes any value to Covi-Drops or SmartPharm applications to Covid or cancer applications. It doesn't mention SP-102 for sciatic pain (phase 3 enrollment complete this month) and excludes any value from RTX for cancer pain. It doesn't refer to the potential ACEA acquisition or assign any value to the Abivirtinib phase 3 NSCLC application. And there is no value assigned to Celularity or to the potential $1 billion PSS lawsuit settlement. It also applies very conservative discount rates. Apart from that...it's clear Sorrento is worth a lot more than $8!
https://dawsonjames.com/wp-content/uploads/2020/12/SRNE.DJ_.12.10.2020.1.pdf?fbclid=IwAR1mxz-f-hDvM0N3G_cbvynm_a7HaVvAti39FHGdEu2QR6tlv8_yVk86Wog